Literature DB >> 26064236

Immunostimulatory activities of dendritic cells loaded with adenovirus vector carrying HBcAg/HBsAg.

Hongyu Jia1, Chunling Li2, Yimin Zhang1, Liang Yu1, Dairong Xiang1, Jun Liu1, Fengzhe Chen3, Xiaochun Han4.   

Abstract

OBJECTIVE: This study is to investigate the immunostimulatory activities of dendritic cells (DCs) transfected with HBcAg and/or HBsAg recombinant adenovirus (rAd).
METHODS: DCs were transfected with rAd (DC/Ad-C+Ad-S, DC/Ad-C, and DC/Ad-S), or pulsed with HBcAg antigen (DC/HBcAg). Flow cytometry was used to detect the phenotype of DCs and the cytokine production of T lymphocytes. Mice were vaccinated with DCs transfected with rAd or pulsed with antigen, and DNA vaccine. Mixed lymphocyte reaction (MLR) was used to evaluate the T-cell stimulatory capacity, and HBcAg-specific cytotoxic T lymphocyte (CTL) activity was assessed.
RESULTS: Phenotypic analysis showed that DCs transfected with rAd or pulsed with HBcAg antigen exhibited mature phenotypes. MLR indicated no significant differences in stimulating T-cell proliferation between the DC/rAd and DC/HBcAg groups. When mixed with DCs, Th and Tc cells mainly secreted IFN-γ, indicating type I immune responses. In vaccinated mice, DCs transduced with rAd and pulsed with HBcAg induced significantly more IFN-γ secretion from Th cells, compared with DNA vaccine, indicating stronger Th1 response. Moreover, DCs transduced with rAd stimulated Tc cells to produce more IFN-γ, indicating stronger Tc1 response. In vaccinated mice, HBcAg-specific CTL activities were decreased in the following order: the DC/Ad-C+Ad-S, DC/Ad-C, DC/Ad-S, DC/HBcAg, and DNA vaccine groups.
CONCLUSION: DCs transfected with rAd induce stronger Th1/Tc1 (type I) cell immune responses and specific CTL response than HBcAg-pulsed DCs or DNA vaccine. Our findings suggest that DCs transfected with rAd-C/rAd-S might provide an effective approach in the treatment of persistent hepatitis B virus infection.

Entities:  

Keywords:  Hepatitis B core antigen (HBcAg); adenovirus; cytotoxic T lymphocytes; dendritic cells (DCs); hepatitis B surface antigen (HBsAg)

Year:  2015        PMID: 26064236      PMCID: PMC4443070     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  The functional consequences of delivery of HIV-1 Nef to dendritic cells using an adenoviral vector.

Authors:  Luci P Maccormac; Jean Marc Jacque; Benjamin Chain
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

2.  Antigen bias in T cell cross-priming.

Authors:  Monika C Wolkers; Nathalie Brouwenstijn; Arnold H Bakker; Mireille Toebes; Ton N M Schumacher
Journal:  Science       Date:  2004-05-28       Impact factor: 47.728

Review 3.  New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors:  Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal:  Virol Sin       Date:  2014-01-17       Impact factor: 4.327

4.  Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells.

Authors:  N Nishimura; Y Nishioka; T Shinohara; S Sone
Journal:  Hum Gene Ther       Date:  2001-03-01       Impact factor: 5.695

5.  Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers.

Authors:  Jin Luo; Jun Li; Rui L Chen; Lei Nie; Jie Huang; Zheng W Liu; Lin Luo; Xiao J Yan
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

6.  A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group.

Authors:  J Heathcote; J McHutchison; S Lee; M Tong; K Benner; G Minuk; T Wright; J Fikes; B Livingston; A Sette; R Chestnut
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

7.  Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2012-07-06

8.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Susceptibility to T cell-mediated liver injury is enhanced in asialoglycoprotein receptor-deficient mice.

Authors:  Benita L McVicker; Geoffrey M Thiele; Carol A Casey; Natalia A Osna; Dean J Tuma
Journal:  Int Immunopharmacol       Date:  2013-03-26       Impact factor: 4.932

10.  A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.

Authors:  Ruihong Zeng; Guangxue Li; Shigan Ling; Heqiu Zhang; Zhiyan Yao; Bingshui Xiu; Feng He; Rui Huang; Lin Wei
Journal:  Antiviral Res       Date:  2009-07-29       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.